

Supplementary Table 1. ASDAS response at weeks 24, 52, and 104.

	Placebo → Golimumab 50 mg (Group 1)	Golimumab 50 mg (Group 2)	Golimumab 100 mg (Group 3)
Proportion of patients with ASDAS score < 1.1			
Week 24	4/72 (5.6)	26/129 (20.2) p = 0.0054	26/136 (19.1) p = 0.0081
Week 52	12/69 (17.4)	27/118 (22.9) p = 0.3726	29/123 (23.6) p = 0.3156
Week 104	11/64 (17.2)	35/104 (33.7) p = 0.0201	29/113 (25.7) p = 0.1952
Proportion of patients with ASDAS score < 2.1			
Week 24	19/72 (26.4)	68/129 (52.7) p = 0.0003	71/136 (52.2) p = 0.0003
Week 52	50/69 (72.5)	79/118 (66.9) p = 0.4315	80/123 (65.0) p = 0.2912
Week 104	50/64 (78.1)	82/104 (78.8) p = 0.9119	74/113 (65.5) p = 0.0778

ASDAS, Ankylosing Spondylitis Disease Activity Score
All data are presented as n (%).